Chronic Study on Body Composition, Training, Performance, and Recovery
A Randomized, Double-blind, Placebo Controlled, Single-center Study to Determine the Effects of Pre-workout and Recovery Formulations on Soreness, Performance, Tolerance and Safety Outcomes in Healthy Adults Undergoing Training Program
1 other identifier
interventional
69
1 country
1
Brief Summary
The chronic phase of the study will evaluate the effects of pre-exercise and post-exercise ingestion of a multi-ingredient supplement on adaptations to a 6-week exercise program consisting of both resistance training and high intensity aerobic exercise, using a randomized, double-blind, placebo-controlled design. Participants will complete an enrollment/familiarization visit, a baseline testing session, followed by a 6-week supervised exercise intervention, and post-testing session identical to baseline testing. Participants will be randomized during the baseline session to groups receiving either 1) Active Treatment (pre-post supplementation), 2) placebo (noncaloric beverage), or 3) control, not participating in exercise or consuming a treatment. During the supervised 6-week resistance training program, participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week). Thirty-minutes prior to each training session, and within 15 minutes post-exercise, participants will consume their randomly assigned treatment beverage. Body composition, blood markers of muscle damage/recovery, strength, and performance tests will be measured before (baseline) and after training (Post) to evaluate the effects of supplementation. All data collection will be conducted by the Principal Investigator and Research Assistants. All subjects will report to the Applied Physiology Laboratory and Human Performance Center in Fetzer Hall for all testing and training sessions, which will span approximately 8 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 13, 2020
CompletedFirst Posted
Study publicly available on registry
January 18, 2020
CompletedStudy Start
First participant enrolled
February 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2022
CompletedJanuary 13, 2022
January 1, 2022
5 months
January 13, 2020
January 12, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Strength
Change from baseline in strength by measuring 1 repetition maximum for leg press and bench press
baseline, week 8
Secondary Outcomes (5)
Muscle soreness
baseline, week 8
Recovery
baseline, week 8
Training Volume
baseline, week 8
Performance
baseline, week 8
Body Composition
baseline, week 8
Study Arms (3)
Pre-workout plus and Protein recovery plus
ACTIVE COMPARATORPre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise
Placebo
PLACEBO COMPARATORNon-caloric powder mixed with water and consumed within 30 minutes prior to exercise and within 15 minutes after exercise
Control
NO INTERVENTIONThis arm will receive no intervention
Interventions
products consumed prior and after exercise
participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
Eligibility Criteria
You may qualify if:
- Participant is an adult between the ages of 25-50 years
- Participant has a recorded BMI of 20-35 kg/m2
- Participant exercises less than 3 hours per week for at least 8 weeks preceding the study
- Participant has provided written and dated informed consent to participate in the study
- Participant is willing to and able to comply with the protocol
- Participant is apparently healthy and no reported metabolic disorders, heart disease, arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as determined by a health history questionnaire
- Participant agrees to maintain current diet and exercise routine during the study
- Participant agrees to refrain from taking any anti-inflammatory supplement 48 hours prior to exercise or for exercise related pain or medications to prevent any further nutritional or drug related protection against exercise induced muscle damage
- Participant agrees to wear an accelerometer to track activity during entire study
- Participant has a resting (seated for 5 minutes) blood pressure of systolic pressure between 140-90 mmHg and a diastolic pressure between 90-50 mmHg
You may not qualify if:
- Participant is currently enrolled in a separate clinical trial or weight loss program involving diet, exercise, physical activity, or the potential ingestion of an active drug or dietary supplement Participant is using, or has consistently used one of the following dietary supplements within 12 weeks prior to enrollment: Beta-alanine, Creatine, HMB, Carnosine, Vitamin D
- Participant has consistently consumed whey protein/plant protein and/or 1,000 mg of fish oil within the previous 4 weeks prior to enrollment
- Participant has gained or lost ≥ 8 lbs in the previous month
- Participant has a known allergy or sensitivity to the placebo or active ingredients
- Participant has used tobacco more than three days per week (on average) in the previous 6 months, or refuses to abstain from all tobacco use for the duration of the study
- Participant is pregnant or planning to become pregnant
- Participant has any musculoskeletal condition prohibiting them from participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pharmanexlead
- University of North Carolina, Chapel Hillcollaborator
Study Sites (1)
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Related Publications (1)
Cabre HE, Gordon AN, Patterson ND, Smith-Ryan AE. Evaluation of pre-workout and recovery formulations on body composition and performance after a 6-week high-intensity training program. Front Nutr. 2022 Nov 2;9:1016310. doi: 10.3389/fnut.2022.1016310. eCollection 2022.
PMID: 36407519DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Abbie Smith-Ryan, PhD
University of North Carolina, Chapel Hill
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 13, 2020
First Posted
January 18, 2020
Study Start
February 1, 2021
Primary Completion
July 1, 2021
Study Completion
January 1, 2022
Last Updated
January 13, 2022
Record last verified: 2022-01
Data Sharing
- IPD Sharing
- Will not share